Pediatric oncology

Seminars in Pediatric Surgery

Volumn 19, Issue 3, 2010, Pages 225-233

  Davidoff, Andrew M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Childhood cancer; Epigenetics; Genetics; Hereditary; Transformation

Indexed keywords

CHIMERIC PROTEIN; DNA; HISTONE; MICRORNA; PROTEIN P53; PROTEIN TYROSINE KINASE; RAS PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PAX7;

ADRENAL TUMOR; APOPTOSIS; ARTICLE; BECKWITH WIEDEMANN SYNDROME; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHILDHOOD CANCER; CHROMOSOME DELETION; DENYS DRASH SYNDROME; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; DNA SYNTHESIS; EPIGENETICS; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GASTROINTESTINAL POLYPOSIS; GENE AMPLIFICATION; GENE TRANSLOCATION; GENETIC CODE; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENOME; GENOTYPE; HEPATOBLASTOMA; HEREDITY; HUMAN; KIDNEY CARCINOMA; KLINEFELTER SYNDROME; MOLECULAR WEIGHT; NEPHROBLASTOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROFIBROSARCOMA; ONCOGENE C MYB; ONCOGENE C MYC; ONCOGENE H RAS; ONCOGENE NEU; OSTEOSARCOMA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN MODIFICATION; RETINOBLASTOMA; SARCOMA; SRC HOMOLOGY DOMAIN; TRANSCRIPTION INITIATION; WAGR SYNDROME; CELL TRANSFORMATION; CHILD; FEMALE; GENETIC EPIGENESIS; GENETIC SCREENING; GENETICS; INCIDENCE; INFANT; MALE; NEOPLASMS; PATHOLOGY; PEDIATRICS; PHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; RISK ASSESSMENT;

CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; EPIGENESIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INCIDENCE; INFANT; MALE; NEOPLASMS; PEDIATRICS; PROGNOSIS; RISK ASSESSMENT;

EID: 77953939471     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2010.03.007     Document Type: Article

References (43)

1. Young J.L., Ries L.G., Silverberg E., et al. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 1986, 58(suppl):598-602.
2. Ries L.G. Childhood cancer mortality. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-95 1999, 165-169. National Cancer Institute, SEER Program, Bethesda, MD. L.G. Ries (Ed.).
3. Bleyer W.A. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990, 40:355-367.
4. Kaneko Y., Kanda N., Maseki N., et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 1987, 47:311-318.
5. Look A.T., Hayes F.A., Nitschke R., et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984, 311:231-235.
6. May W.A., Gishizky M.L., Lessnick S.L., et al. Ewing sarcoma 11; 22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993, 90:5752-5756.
7. May W.A., Lessnick S.L., Braun B.S., et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993, 13:7393-7398.
8. Sorensen P.H., Lessnick S.L., Lopez-Terrada D., et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994, 6:146-151.
9. Galili N., Davis R.J., Fredericks W.J., et al. Fusion of a fork head domain gene to Pax3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993, 5:230-235.
10. Barr F.G. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer Res 1999, 59(suppl):1711s-1715s.
11. Sorensen P.H., Lynch J.C., Qualman S.J., et al. Pax3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 2002, 20:2672-2679.
12. Davidoff A.M., Hill D.A. Molecular genetic aspects of solid tumors in childhood. Semin Pediatr Surg 2001, 10:106-118.
13. Chen Y., Takita J., Hiwatari M., et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 2006, 45:583-591.
14. Kohl N.E., Kanda N., Schreck R.R., et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983, 35:359-367.
15. Lutz W., Stohr M., Schurmann J., et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996, 13:803-812.
16. Brodeur G.M., Hayes F.A., Green A.A., et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987, 47:4248-4253.
17. Seeger R.C., Brodeur G.M., Sather H., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
18. Kusafuka T., Fukuzawa M., Oue T., et al. Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 1997, 32:1175-1180.
19. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
20. Brodeur G.M., Sekhon G., Goldstein M.N. Chromosomal aberrations in human neuroblastomas. Cancer 1977, 40:2256-2263.
21. Fong C.T., Dracopoli N.C., White P.S., et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci U S A 1989, 86:3753-3757.
22. Fujita T., Igarashi J., Okawa E.R., et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008, 100:940-949.
23. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353:2243-2253.
24. Grundy P., Coppes M.J., Haber D. Molecular genetics of Wilms tumor. Hematol/Oncol Clin North Am 1995, 9:1201-1215.
25. Grundy P.E., Breslow N.E., Li S., et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 2005, 23:7312-7321.
26. Teitz T., Wei T., Valentine M.B., et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6:529-535.
27. Fulda S., Kufer M., Meyer E., et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20:5865-5877.
28. Ruvkun G. Molecular biology. Glimpses of a tiny RNA world. Science 2001, 294:797-799.
29. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
30. Wei J.S., Johansson P., Chen Q.R., et al. MicroRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009, 15:5560-5568.
31. Quesnel S., Malkin D. Genetic predisposition to cancer and familial cancer syndromes. Pediatr Clin North Am 1997, 44:791-808.
32. Coppes M.J., Haber D.A., Grundy P.E. Genetic events in the development of Wilms' tumor. N Engl J Med 1994, 331:586-590.
33. Call K.M., Glaser T., Ito C.Y., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
34. Pritchard-Jones K., Fleming S., Davidson D., et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990, 346:194-197.
35. Ton C.C., Hirvonen H., Miwa H., et al. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell 1991, 67:1059-1074.
36. Pelletier J., Bruening W., Kashtan C.E., et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991, 67:437-447.
37. Varanasi R., Bardeesy N., Ghahremani M., et al. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci U S A 1994, 91:3554-3558.
38. Coppes M.J., Bonetta L., Huang A., et al. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination. Genes Chromosomes Cancer 1992, 5:326-334.
39. Koufos A., Grundy P., Morgan K., et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989, 44:711-719.
40. Mosse Y.P., Laudenslager M., Longo L., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
41. Maris J.M., Mosse Y.P., Bradfield J.P., et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008, 358:2585-2593.
42. Capasso M., Devoto M., Hou C., et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009, 41:718-723.
43. Diskin S.J., Hou C., Glessner J.T., et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009, 459:987-991.